全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2019 

Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps

DOI: 10.1177/1945892418814768

Keywords: chronic rhinosinusitis,nasal polyposis,biologic agents,anti-IgE,anti-IL-4,anti-IL-5,anti-IL-13,GATA-3 DNAzyme,omalizumab,reslizumab,mepolizumab,benralizumab,dupilumab,Hgd40,SB010

Full-Text   Cite this paper   Add to My Lib

Abstract:

Chronic rhinosinusitis with nasal polyposis is a complex inflammatory disorder, which is often recalcitrant to medical and surgical management. Recently, biologic agents have been studied as an adjunct treatment for this patient population. The purpose of this study is to examine the role of biologic agents for chronic rhinosinusitis patients by reviewing literature and clinical trials. A comprehensive review of literature and clinical trials—both recently completed and ongoing—was undertaken to examine up-to-date evidence of current biologic therapy and its role in chronic rhinosinusitis patients—including anti-IgE, anti-IL-4, anti-IL-5, anti-IL-13, and GATA-3 DNAzyme. Specific biologic agents discussed include omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, and Hgd40/SB010. Risks, side effects, and administration information are also reviewed. An algorithm for the use of biologics in patients with chronic rhinosinusitis with nasal polyposis is proposed. These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133